Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • đŸ”„
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Paratek expands commercial portfolio with Optinose
Economy

Paratek expands commercial portfolio with Optinose

Last updated: May 22, 2025 8:01 am
Share
Paratek expands commercial portfolio with Optinose
SHARE

Paratek Pharmaceuticals has recently finalized the acquisition of Optinose, a deal valued at nearly $330 million. This strategic move has significantly expanded Paratek’s commercial product offerings, solidifying its position in the pharmaceutical market.

The merger agreement between the two companies was officially signed in March 2025, paving the way for a comprehensive consolidation of their respective portfolios. Paratek’s lineup now includes its flagship antibiotic, Nuzyra (omadacycline), as well as Optinose’s Xhance (fluticasone propionate), a key addition to their product range.

The acquisition encompasses all outstanding shares of Optinose, including debt assumption and full payment of contingent value rights (CVRs). Shareholders of Optinose gave their approval for the merger on 16 May, marking a significant milestone in the consolidation process. Capital for the transaction was provided by Paratek, Novo Holdings, and B-FLEXION Life Sciences, with additional debt financing from Oaktree Capital Management funds.

Under the terms of the agreement, Optinose shareholders received $9 per share in cash and CVRs worth up to $5 per share, contingent upon Xhance achieving specific net revenue milestones. Paratek has committed to paying $1 per share upon Xhance reaching $150 million in net sales in any calendar year before 31 December 2028, and an extra $4 per share if the sales hit $225 million before 31 December 2029.

Nuzyra, Paratek’s leading antibiotic, is designed to combat tetracycline resistance and is effective against a wide range of bacteria, including drug-resistant strains. It is available in both oral and intravenous formulations for the treatment of community-acquired bacterial pneumonia and acute bacterial skin infections. On the other hand, Xhance, a drug-device combination product from Optinose, utilizes the exhalation delivery system to deliver the topical steroid to the deep nasal cavity areas.

See also  Should Investors Add John Wiley & Sons (WLY) to Their Dividend Champions Portfolio?

CEO of Paratek Pharmaceuticals, Evan Loh, expressed his excitement about the acquisition, stating that adding Xhance to their portfolio is a significant step towards achieving their long-term goal of becoming a multi-product specialty therapeutics company. He emphasized the importance of addressing unmet medical needs and leveraging their capabilities to explore future opportunities for portfolio expansion through additional product acquisitions.

Lazard and Skadden, Arps, Slate, and Meagher & Flom provided exclusive financial and legal advisory services to Paratek during the acquisition process, while Evercore and Hogan Lovells US assisted Optinose. The successful integration of Optinose into Paratek’s commercial portfolio marks a new chapter for the company, setting the stage for continued growth and innovation in the pharmaceutical industry.

The article “Paratek expands commercial portfolio with Optinose” was originally published by Pharmaceutical Technology, a GlobalData-owned brand, providing valuable insights into the latest developments in the healthcare sector.

TAGGED:commercialexpandsOptinoseParatekportfolio
Share This Article
Twitter Email Copy Link Print
Previous Article Bird Flu Vaccine for Cows Passes Early Test Bird Flu Vaccine for Cows Passes Early Test
Next Article Two women arrested for allegedly helping fugitives who broke out of New Orleans prison Two women arrested for allegedly helping fugitives who broke out of New Orleans prison
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

We Finally Know What Switched on The Lights at The Dawn of Time : ScienceAlert

We Finally Understand the Origins of Light in the Early Universe Recent data from the…

November 7, 2024

Samsung Galaxy Z Flip 7 Survives Bend Test

Samsung’s latest compact foldable flagship phone, the Galaxy Z Flip 7, has undergone a rigorous…

August 5, 2025

Reverse mortgage vs. home equity loan vs. HELOC: Which is best?

Your home is not just a place to live; it's also a valuable financial asset.…

May 12, 2025

Drysdale finally buys house – but mayor not moving in yet

Tauranga Mayor MahĂ© Drysdale has recently purchased a home in Pāpāmoa, although he and his…

May 16, 2025

Leonardo DiCaprio Grabs Lunch With Al Pacino, Gives Him Ride Home in Porsche

Leonardo DiCaprio recently enjoyed a lunch date with Hollywood legend Al Pacino at the Bird…

December 18, 2024

You Might Also Like

BTIG Remains Positive on NextEra Energy (NEE), Highlighting its “Premier Generation Development Platform”
Economy

BTIG Remains Positive on NextEra Energy (NEE), Highlighting its “Premier Generation Development Platform”

October 31, 2025
3 Must-Buy Stocks Fueling the Data Center Surge
Economy

3 Must-Buy Stocks Fueling the Data Center Surge

October 31, 2025
Shake Shack returns to profit in Q3 2025
Economy

Shake Shack returns to profit in Q3 2025

October 31, 2025
Fresnillo signs agreement to acquire Probe Gold for 8m
Economy

Fresnillo signs agreement to acquire Probe Gold for $558m

October 31, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?